The Super Patch Company
The one company in this category that actually ran a registered, randomised, double-blind, sham-controlled trial and published it in a PubMed-indexed journal - and then built its official 60-day earnings illustration entirely out of recruiting, published no income disclosure in any market, and left 100% of its BBB complaints unanswered.
There is no income disclosure statement in any market, and the company’s own Associate Handbook teaches a 60-day plan paying $390 to $1,651 in which every single dollar comes from enrolling associates onto kits and $90 autoship - retail commission is described as "extra."
Can you actually make money with Super Patch?
No. Not on what this company publishes about earnings, which is nothing. It sells in the United States, Canada, the United Kingdom and Germany and has never published an income disclosure statement in any of them. No median, no average, no share of associates earning nothing. A prospect cannot test a single claim a sponsor makes against a single published figure, in any of those four markets.
The cost side is knowable, which makes the gap sharper. Holding a minimum position for a year is $1,130 - a $50 Welcome Kit plus twelve months of $90 SmartShip. Holding a bonus-eligible position is $1,629, because the fast-start bonuses assume a Launch Kit at $250 to $650. Covering that $1,629 from retail margin alone takes about $6,516 of retail volume at the 25% base commission, which is roughly $108 of patches sold every week.
And the one earnings illustration the company does publish is built entirely out of recruiting. The Associate Handbook's sixty-day plan pays $390 at Qualified Associate and $1,651 at Team Leader, and every component of it - Hat Trick, All-Star, Rank Advancement, the Down Line Bonus - is triggered by other people joining and buying kits and $90 autoship. The same document describes retail commission as extra and in addition to those earnings.
What is real here is rarer in this category than the grade suggests. A registered, randomised, double-blind, sham-controlled trial, n=118 with a visually identical sham, published in a PubMed-indexed journal in December 2025. No FDA warning letter, no FTC action and no state attorney-general action anywhere, ever. Monthly qualification is also satisfiable with $120 of retail sales volume instead of the $90 SmartShip, so the plan does at least contemplate customers.
nominal Welcome Kit including $75 of product - but the fast-start bonuses the plan is built around require a Launch Kit at $250–$650, with sources putting the threshold for "all bonuses" at $549 or over $600, then $90 a month in SmartShip to stay commission-qualified
- A published income disclosure in each of the four markets it sells in. Sponsors are making earnings claims in the United States, Canada, the United Kingdom and Germany with no company figure anywhere that a prospect could hold them against.
- A sixty-day illustration that pays for selling something. As written, every dollar of the handbook's $390 to $1,651 comes from enrolling associates onto kits and autoship, and the document itself calls retail commission extra.
- Policies, the Associate Agreement and the compensation plan published as readable documents at stable addresses. Two of the three return 404 and 403 today, and the third exists only as a flipbook that contradicts itself on the unilevel percentages between pages 40 and 41.
- Answered complaints. Nine or ten BBB complaints over three years are all logged as failure to respond, from a company that paid a third-party monitoring vendor in the same period to satisfy an industry self-regulator.
That call is computed, not chosen - the rule reads three of the nine published dimension scores and is printed on the methodology page. It describes this company's plan and the figures it publishes about the people already in it. It is not a prediction about you, and nothing on this site is advice.
Legal status
LEGAL BUT - no government regulator anywhere has taken action. No FDA warning letter, untitled letter, injunction, seizure or import alert; no FTC complaint, consent order or stipulated judgment; no state attorney-general action; no class action; no court finding of any kind in the United States, Canada, the United Kingdom or Germany. The file contains four things short of that. VoxxLife, the founder’s prior venture, appears on the published recipient list of the FTC’s October 2021 Notices of Penalty Offenses Concerning Money-Making Opportunities - a warning notice sent to more than 1,100 companies, not a charge, not an allegation against that company specifically, and not a finding. The Direct Selling Self-Regulatory Council opened Case #242-2025 into salesforce income claims and closed it administratively on 9 December 2025 after the company removed nine of ten posts, established the tenth poster had no affiliation, retrained compliance and engaged a third-party social-monitoring vendor; DSSRC called the corrective action "necessary and appropriate" and made no FTC referral. TINA.org published a detailed watchdog report in July 2024 on health and regulatory claims - a non-governmental finding, never adjudicated by anyone. And the Better Business Bureau, a private ratings body and not a regulator, rates the Mississauga entity F with every complaint on file logged as unanswered.
Confidence: Medium
Primary sources fetched directly where possible. Everything we could not verify is listed at the bottom of this page by name.
Follow the money
A Mississauga company selling small adhesive plastic patches embossed with a raised ridge pattern, through retail and subscription customers and through a recruited salesforce of Independent Associates who buy at a discount and earn on downline volume. There is no battery, no drug, no chemical and no electronics; the claimed mechanism is that the ridge pattern mechanically stimulates skin receptors and thereby modulates nervous-system processing of pain, sleep, balance, stress, focus, energy, metabolism and mood. And the first thing to say about it - before anything critical - is that this company has done something almost nobody in its category does. It ran a prospective, randomised, double-blind, sham-controlled trial with a visually identical placebo patch, registered it on ClinicalTrials.gov as NCT06505005, enrolled 118 participants, and published the results as the RESTORE study in Pain and Therapy, a peer-reviewed Springer/Adis title indexed in PubMed, in December 2025. Active-group participants showed significantly greater improvement in Brief Pain Inventory severity and interference and in objective range of motion at days 7 and 14. That is a real trial in a real journal and it must be credited.
Now the limits of it, which are equally real. The trial is wholly sponsor-funded. All three authors - Fason, Gudin and Hurwitz - are compensated, and Hurwitz is President of Clarity Science LLC, the contract research organization that ran it. Follow-up is fourteen days, so nothing durable is demonstrated. The primary endpoints are largely self-reported, which makes blinding integrity decisive, and no blinding-integrity check appears in anything retrievable - for an intervention whose entire claimed mechanism is a tactile sensation, a smooth sham and a ridged active patch feel different on the skin, so the double-blind is an assertion rather than a demonstration. There is no independent replication. And the trial covers one product. Eleven or more other marketed patches have no controlled evidence at all, the company publicly claims "16 published studies" against two indexed in PubMed with no list of the other fourteen published anywhere, and the Ignite patch is sold on a "25 Percent Improvement in Resting Metabolic Rate" claim for which no study could be located. Independent examination by the Quebec Pain Research Network found "no vibrations are detectable and there are no apparent internal components."
The regulatory framing is where a reader gets the most useful single thing from this report. Three different things are being conflated in the marketing and they need separating. FDA establishment registration and device listing is a paperwork formality: a firm tells the FDA it exists and what it makes. The FDA reviews nothing, evaluates no evidence and endorses nothing, and it expressly prohibits representing registration as approval. A 510(k) clearance is a substantive submission in which the agency reviews evidence that a device is substantially equivalent to a legally marketed predicate - no 510(k) clearance exists for Super Patch, Srysty or VoxxLife. Premarket approval, the highest tier, is not in play at this risk class. Separately again, the FDA’s general-wellness policy is an enforcement-discretion carve-out: if a product’s intended use is limited to general wellness and it is low risk, the agency will not enforce device requirements against it. Against that map, presenting "FDA registered" as "the highest level of regulatory approval," as TINA.org documented in July 2024, is the single most misleading thing in this file - it takes the lowest and most clerical rung on the ladder and labels it the highest. Meanwhile the company’s own trademark filing describes the product to the USPTO as International Class 10 medical apparatus "for stimulating trigger points for energy, pain management, mobility, stability and balance," and the Ignite page carries a dietary-supplement disclaimer that has no application to devices at all.
The economics are simpler and they are the reason for the grade. There is no income disclosure statement in any market - none in the United States, none in Canada, none in the United Kingdom, none in Germany. In its place the official Associate Handbook publishes a 60-day plan called "You Plus 3 · Them Plus 3": join with a $90 SmartShip and a Launch Kit, recruit three associates who do the same, then help each of them recruit three more. Qualifying at Qualified Associate pays a $200 Hat Trick Bonus, a $70 Down Line Bonus and a $120 Business Builder’s Product Bonus - $390. Qualifying at Team Leader pays a $500 rank advancement bonus, a $400 All-Star Bonus, a $241 Down Line Bonus and $120 of product - $1,261, or $1,651 across the 60 days. Every component is triggered by somebody else joining and buying. The handbook adds that "Retail Commission from Customer Sales is Extra and in Addition to These Earnings," which is a plain statement that customers sit outside the model. And the qualification gate is $90 of personal autoship or $120 of retail sales, so serving actual customers costs a third more than buying the product yourself.
Where the handbook’s own $1,651 comes from
The official Associate Handbook’s "You Plus 3 · Them Plus 3" 60-day illustration, page 46, at the Team Leader qualification. Components as the company itself sets them out. No income disclosure statement exists in any market against which a prospect could test whether any measurable share of associates reaches this.
| Product | Price | Pays |
|---|---|---|
| Associate enrollment - Welcome Kit Includes "$75 of FREE Super Patches," wholesale pricing at "25%++ discounts" and a replicated website. Genuinely modest as an entry price, and worth saying so - but it is not the kit the handbook’s own 60-day plan requires. |
$50 one-time |
— |
| Launch / Business Builder Kits The kits that unlock the fast-start bonuses. Sources diverge - $275–$650 in one, $50–$999 in another, "$549 to access all bonuses" in a third, "over $600" in a fourth. Kit pricing is not published on the consumer site and the current ladder could not be confirmed. |
$250 · $450 · $650 one-time |
— |
| Personal SmartShip (autoship) The cheaper of the two routes to monthly commission qualification, and the one the handbook’s illustration assumes. $1,080 a year. Cancellation is by email to opportunity@superpatch.com with at least three calendar days’ notice before the next charge. |
$90/mo recurring |
— |
| Retail qualification - the other route Qualifying by selling to real customers requires a third more volume than qualifying by buying product yourself. A plan that makes self-purchase the cheaper path to qualification will generate self-purchase. |
$120/mo of sales volume recurring |
25% base |
| Retail patch pack (REM, Freedom, Peace, Liberty and others) $2.14 per patch, one patch per day, so roughly $720 a year for daily use of a single patch type. Multi-patch users are reported at $60–$99 a month, or $720–$1,200 a year. |
$60 per 28-pack per unit |
25% on BV |
| Preferred Customer subscription Same 28-pack on subscription, marketed with "$10 Off + Subscribe & Save" and a free four-patch sample "valued at $15." The genuine customer channel, and the one the compensation plan pays least attention to. |
$60/mo recurring |
25% |
| Practitioners Program Health-care practitioners enrol free and buy at half price. This is the source of the "RECOMMENDED BY 1,000’S OF DOCTORS" homepage banner - no list, no count methodology, and no distinction drawn between a doctor who recommends the product and a doctor enrolled in a half-price reseller program. |
free to join · 50% off retail ongoing |
— |
| Ignite patch Sold on "25 Percent Improvement in Resting Metabolic Rate" and "burn more calories throughout the day, even while sitting, relaxing, commuting to work or school, or sleeping." No supporting study could be located. The page carries a dietary-supplement disclaimer, which has no application to a device. |
$60 per 28-pack per unit |
25% on BV |
Who runs it, and what they ran before
Named, identifiable, on the record in executive interviews, and fifteen years into the same technology thesis - which is meaningfully better than the anonymous-operator norm in this category and is scored as such. No regulatory action, fraud judgment or criminal proceeding against him could be located in any jurisdiction. Two qualifications. He is a listed author on "Changes in Electroencephalogram (EEG) After Foot Stimulation with Embedded Haptic Vibrotactile Trigger Technology," research supporting his own product - the surname, subject and timing align, though the record could not be fully retrieved to confirm identity. And the mechanism he sells now is the mechanism he sold before, on a different substrate.
VoxxLife sold socks and insoles embossed with a "vibrotactile technology" pattern, making essentially the claim Super Patch now makes for adhesive patches. VoxxLife appears on the published recipient list of the FTC’s October 2021 Notices of Penalty Offenses Concerning Money-Making Opportunities. Stage-label this precisely: it is a warning notice, sent to over 1,100 companies at once, and it is not an enforcement action, a complaint, a consent order or a finding of any wrongdoing by that company. What it does do is put the recipient formally on notice that misrepresenting earnings potential has been held unlawful in prior Commission proceedings, with civil-penalty exposure - reported at up to $51,744 per violation at the time - attaching to future violations. That knowledge does not evaporate when a new brand is incorporated. VoxxLife’s current status could not be confirmed; a tools subdomain at tools.superpatch.com/VoxxLife/ and distributor sites selling both lines together suggest the salesforces are cross-linked, which is inference and not a company statement.
Named in the company-supplied executive list published by Direct Selling News in February 2025 and in the German entity’s incorporation record as reported by BehindMLM. The wider named bench - a chief operating officer, a chief procurement officer and a creative director - is also company-supplied and could not be independently corroborated. Headcount is published nowhere. The media contact on the June 2026 press release shares the founder’s surname, which is consistent with a closely held family business and is noted as context rather than criticism.
Every published study supporting the product carries some combination of Fason, Gudin and Hurwitz. Peter Hurwitz is President of Clarity Science LLC, the contract research organization that ran the trials, and was compensated; the other two were compensated as investigators; the sponsor is the company. The 2024 observational paper states its funding verbatim as coming from "Srysty Holding Co., the distributors of the FREEDOM Super Patch with VTT." No independent replication of any result by investigators without a financial relationship to the company or to Clarity Science exists. This does not make the findings wrong. It does mean that the entire efficacy literature for this product is the sponsor’s own, and a reader has no outside check on it.
Registered address
Mississauga, Ontario, Canada
Privately held, no public accounts, no securities registration, no named auditor anywhere in the record. The US storefront footer identifies the operating entity as "The Super Patch Company Limited LLC" - a hybrid string that does not correspond to a recognized corporate form in either Canada or any US state, and which the company does not explain. The brand asset sits somewhere else again: the trademark applicant is Srysty Holdings Inc. at a separate Mississauga address, and the funder named in the company’s own 2024 research paper is "Srysty Holding Co., the distributors of the FREEDOM Super Patch with VTT." A holding-company-over-operating-company structure is lawful and ordinary, but it means the entity a participant contracts with is not the entity that owns the brand. Ontario and German registry filings could not be retrieved, so incorporation dates, directors of record and share structure are unverified. Four incompatible revenue narratives circulate: a trade site estimating $10M in 2022, $55M in 2023, $100M in 2024 and $100M again in 2025 at 0% growth; $60M for 2023 supplied by the company to Direct Selling News; a ~$120M projection; and a "$200M revenue run rate" reported by consumer press in June 2026. None is audited. The company does not appear on the 2026 Direct Selling News Global 100.
The veteran's checklist
Eight questions that decide whether this is a business or a transfer mechanism. Same eight, every review.
| Question | Answer |
|---|---|
| Who legally owns it? |
CONCERN
The Super Patch Company Ltd of Mississauga, Ontario, privately held and controlled by founder Jay Dhaliwal. The trademark sits in Srysty Holdings Inc., a separate Ontario corporation, and the US storefront names "The Super Patch Company Limited LLC," a form that does not exist. No registry filings, audited accounts, named auditor or headcount could be retrieved.
|
| What does it really cost? |
CONCERN
$50 to enrol, or $250–$650 for the Launch Kit the fast-start bonuses require, plus $90 a month in SmartShip to stay commission-qualified. Independently computed year-one floors are $1,130 basic and $1,629 for full bonus access, before events, tools, travel and samples, none of which is priced publicly.
|
| Published income disclosure? |
RED
No. None exists in the United States, Canada, the United Kingdom or Germany. The company publishes the top of the distribution instead - "$100,000 monthly," "three millionaires," and a handbook illustration of $390 to $1,651 in 60 days - with nothing about the middle or the bottom.
|
| Does the product work? |
WATCH
One patch has real evidence: a registered, randomised, double-blind, sham-controlled trial with 118 participants published in Pain and Therapy in December 2025, showing pain and range-of-motion improvement at 14 days. It is entirely sponsor-funded, authored by three compensated investigators, has no blinding-integrity check and no independent replication. Eleven or more other marketed patches have no controlled evidence at all.
|
| Is it FDA approved? |
RED
No. There is no 510(k) clearance and no premarket approval for Super Patch, Srysty or VoxxLife. A watchdog reported four of twelve patches listed as Class I devices - establishment registration and listing, which is a clerical filing involving no FDA review of the device and no endorsement. Presenting that as "the highest level of regulatory approval" is the most misleading claim in this file.
|
| Any regulator taken action? |
WATCH
None anywhere. No FDA letter, no FTC action, no attorney-general action, no class action, no court finding. A DSSRC inquiry into salesforce income claims closed administratively on 9 December 2025 with no adverse finding and no FTC referral. The founder’s prior venture received an FTC Notice of Penalty Offenses in October 2021 - a warning notice sent to over 1,100 companies, not a charge.
|
| Can you get your money back? |
CONCERN
A "full, 30-day, money-back guarantee" that accepts only unopened original packaging, makes shipping non-refundable and puts return postage on the buyer. The BBB file records an $818.12 order refunded at $586.15 after a $231.97 restocking fee, and nine to ten complaints over three years all logged as unanswered - a private ratings body’s F, not a regulator’s finding.
|
| Merchant play or miner play? |
RED
Miner. Retail pays 25%, which is workable, but every rank above the first is defined by legs of associates rather than customers, qualifying by selling costs $120 where qualifying by buying costs $90, and the handbook’s own 60-day illustration pays $390 to $1,651 with retail commission explicitly described as sitting outside it.
|
What has to be true for you to get paid
| To cover | You need |
|---|---|
| Hold a minimum associate position for one year | $1,130 $50 Welcome Kit plus twelve months of $90 SmartShip |
| Hold a bonus-eligible position for one year | $1,629 $549 Launch Kit plus twelve months of $90 SmartShip |
| Cover that $1,629 from retail margin alone | ~$6,516 of retail volume at the 25% base commission on Bonus Value, about $108 of patches sold every week |
| Earn the handbook’s advertised $1,651 | 12 associates onto kits and $90 autoship in 60 days you plus three, each of them plus three - the illustration pays nothing for customers |
Read this twice
This arithmetic is unusual on this site because half of it cannot be written. The cost side is knowable: $50 to enrol, $250–$650 for the Launch Kit that the fast-start bonuses require, $90 a month in SmartShip or $120 a month of retail volume to stay commission-qualified, and an independently computed year-one floor of $1,130 basic or $1,629 for full bonus access. Nothing in that figure covers events, conventions, travel, lead tools, samples given away or the replicated-site cost beyond year one, none of which is priced anywhere public, so the realistic all-in for someone actually working the business is materially above $1,629. The earnings side is simply absent. There is no income disclosure statement in the United States, Canada, the United Kingdom or Germany, so there is no median, no average, no zero-earner percentage and no rank distribution - nothing to divide the cost by. Three things belong here in fairness. The plan is a unilevel with a depth extension, not a binary, so there is no volume flushing and no cycle mechanic to lose money to. The entry price at the bottom rung is genuinely small in absolute terms: $50, including $75 of product. And commissions do appear to be paid on time - the complaint record concerns refunds and cancellations, not unpaid commissions. Set against those: qualifying by selling costs $120 where qualifying by buying costs $90, the 60/40 rule caps how much qualifying volume may come from one leg, the money-back guarantee accepts unopened packaging only with the buyer paying return postage, and the customer-to-associate sales ratio - the number that would settle whether any of this is funded by real outside demand - is not published and cannot be derived.
Run your own numbers
Drag the sliders. Nothing here is stored or sent.
Twenty-five per cent retail on a customer spending about $60 a month. Cost is the $90 monthly autoship that keeps you commission-qualified - note that qualifying by selling costs about $120, a third more than qualifying by buying it yourself, which tells you which behavior the plan prefers. There is no income disclosure statement in any market, so there is nothing to calibrate this against. Your own subscription cost of $90/mo is included.
What it costs to replace this yourself
Super Patch sells a $60 pack of 28 embossed adhesive patches - $2.14 for each day of use - against claimed outcomes in sleep, balance, pain and focus. This table sets the retail price beside what the open market charges to address the same four outcomes. Hold one number in mind while reading it: the Practitioners Program enrols health-care practitioners free of charge and supplies them at 50% off retail. A channel that pays nothing to join and generates no downline volume has to be profitable on its own, so the cost of goods on a $60 pack of printed plastic sits well under $30 and, on any sane manufacturing assumption, far below that.
| What they sell you | What you'd use instead | Your cost |
|---|---|---|
| REM sleep patch - $60 per 28-pack, $2.14 a night | Sleep hygiene basics - fixed schedule, blackout blind, no screens - plus an over-the-counter sleep aid if genuinely needed | $0–15/mo |
| Freedom pain patch - $60 per 28-pack | Generic topical analgesic patches or an over-the-counter oral analgesic at pharmacy prices | $6–15/mo |
| Liberty balance and mobility patch - $60 per 28-pack | Published balance and gait programs, free; one physiotherapy assessment if the balance problem is real | $0, or one clinic visit |
| Focus patch - $60 per 28-pack | Sleep, caffeine at a sensible dose, and a free timer app | $0–10/mo |
| Peace stress patch - $60 per 28-pack | Free breathing and mindfulness protocols; a subscription meditation app if you want the structure | $0–13/mo |
| Ignite metabolic patch - $60 per 28-pack, on a "25% improvement in resting metabolic rate" claim | Nothing on the open market claims that for a sticker; the honest comparator is a daily walk | $0 |
| Multi-patch daily use - $60–$99/mo, $720–$1,200 a year | Buying only the thing with evidence behind it, only when you need it | $0–30/mo |
| $90 monthly SmartShip to stay commission-qualified | No qualification requirement, no rank, no monthly floor, no forfeiture | $0 |
| Total as sold ~$1,629 in year one at the bonus-eligible kit |
Total, built yourself ~$0–360 of open-market equivalents |
Price-to-value
The gap here is not a product premium, it is a plan premium. A salon-priced consumable at two or three times an open-market equivalent is an ordinary trade in direct selling; $60 for 28 printed plastic stickers, supplied to a free-to-join practitioner channel at half that, against outcomes the open market addresses for between nothing and fifteen dollars a month, is a different kind of gap. One caveat that cuts the company’s way and belongs here: 1,074 Trustpilot reviews averaging 4.0 and an eBay secondary market in which sealed packs resell at or above the $60 retail price rather than being dumped at a discount are a genuine demand signal. Some people buy this because they want it. The question this report exists to answer is whether enough of them would keep buying it at $60 if the income opportunity did not exist, and no published number lets anyone answer that.
Three operators, five horizons
Probability of cumulative net profit
Hover any point for median, top decile and bottom quartile.
Enrolled for the discount
joins at $50, holds the $90 SmartShip, uses the patches, never recruits
| Horizon | P(profit) | Median |
|---|---|---|
| 3 mo | 4% | −$320 |
| 6 mo | 5% | −$590 |
| 1 yr | 6% | −$1,130 |
| 3 yr | 6% | −$3,300 |
| 5 yr | 6% | −$5,400 |
Part-time associate
10 hrs/wk, a $549 kit, a handful of customers and some recruiting
| Horizon | P(profit) | Median |
|---|---|---|
| 3 mo | 6% | −$820 |
| 6 mo | 8% | −$1,300 |
| 1 yr | 10% | −$2,100 |
| 3 yr | 11% | −$5,200 |
| 5 yr | 11% | −$8,000 |
Full-time builder
30+ hrs/wk, working the You Plus 3 plan, kits, events and travel
| Horizon | P(profit) | Median |
|---|---|---|
| 3 mo | 3% | −$1,900 |
| 6 mo | 6% | −$3,300 |
| 1 yr | 8% | −$6,000 |
| 3 yr | 10% | −$14,000 |
| 5 yr | 10% | −$21,000 |
Methodology note. ANCHORED to the published cost side and to the plan mechanics, all of which are documented: the $50 Welcome Kit including $75 of product; Launch Kits at $250, $450 and $650 with $549 cited as the threshold for full bonus access; the $90 monthly SmartShip and the $120 monthly retail alternative; the 25% base commission on Bonus Value; the $200 Hat Trick, $400 All-Star and $50/$250/$1,500 Power of 3 bonuses; rank advancement bonuses of $500 to $50,000; the Total Group Qualification Volume ladder of 540 at Qualified Associate, 3,000 at Team Leader, 11,000 at Director and 33,000 at Managing Director; the 60/40 single-leg cap; $60 per 28-pack retail; and the independently computed year-one floors of $1,130 and $1,629. MODELED by us: every figure on the earnings side, without exception. That has to be stated more loudly here than anywhere else on this site, because there is no income disclosure statement in any market - no median, no average, no zero-earner share, no rank headcounts, no expense data. The share of each cohort in cumulative profit, the medians, the top and bottom deciles and the cohort definitions themselves are ours, built from the plan mechanics and from the distribution shape that published disclosures in comparable unilevel plans consistently show. They are an informed estimate, not a reading of a company document, and if the company published a disclosure tomorrow this table should be replaced by it. Two calibrations that cut the company’s way are already inside the numbers: the unilevel structure has no flushing pathology, and the $50 entry means the downside for the first cohort is bounded by what they choose to spend on product rather than by a forfeited package.
Where you are actually allowed to promote this
Platform policy reads, not verifications. Check every one before you spend a dollar - enforcement changes faster than the written policy does.
Red flags and green flags
Red flags
151No income disclosure statement exists in any market
2The handbook’s own 60-day earnings plan is entirely recruitment-funded
3Serving customers costs a third more than buying product yourself
4"FDA registered" presented as "the highest level of regulatory approval"
5Disease claims run through the whole channel, including the company’s own material
6The mechanism does not survive physical inspection
7Every study is sponsor-funded, by the same three authors, through the same CRO
8"16 published studies" against two indexed in PubMed
9A quantified metabolic claim with a supplement disclaimer on a device
10The governing contract cannot be read before you join
11The official plan document contradicts itself
12The money-back guarantee is materially narrower than advertised
13One hundred percent of BBB complaints logged unanswered
14The growth story is stale, unaudited and internally contradicted
15The founder relaunch pattern
Green flags
81A genuinely registered, randomised, double-blind, sham-controlled trial exists
2No government enforcement action anywhere, ever
3The DSSRC inquiry was resolved cooperatively and closed with no adverse finding
4Product safety risk is genuinely low
5No securities-type exposure of any kind
6Unilevel rather than binary
7A small, transparent entry price at the bottom rung
8A real consumer demand signal, independent of the opportunity
We would like to be wrong about this
Upward
- Publishing a genuine income disclosure statement covering every market, with median and modal earnings, the percentage earning nothing and costs netted out - the single largest available upgrade, followed by publishing the Policies and Procedures, the Associate Agreement and a self-consistent compensation plan as downloadable PDFs at stable public URLs.
- Independent replication of the RESTORE result by investigators with no financial relationship to the company or to Clarity Science, in a specialty journal, with a published blinding-integrity check - plus publishing the enumerated list of the claimed "16 published studies" with journals, designs, indexing status and funding.
- Dropping the "FDA registered means highest level of regulatory approval" framing and the Ignite metabolic-rate claim, answering the outstanding BBB complaints, and equalising the qualification gate so that $90 of retail sales qualifies exactly as $90 of autoship does.
Downward
- Any FDA warning letter or untitled letter over device claims, any Health Canada or MHRA action, or any FTC action - the October 2021 Notice of Penalty Offenses served on the founder’s predecessor company materially raises the civil-penalty exposure attaching to a repeat.
- A second DSSRC inquiry, particularly one concerning health claims rather than income claims, or one referred to the FTC rather than closed administratively.
- Confirmation that revenue was flat or declining while recruitment messaging intensified, evidence that autoship volume is predominantly associate self-purchase rather than genuine customer purchase, or rapid new-market cycling with entry recruitment pushes while established markets go flat.
Grade is D−. A real registered trial and a clean government record, attached to no income disclosure anywhere, an official 60-day plan funded entirely by recruiting, and a regulatory claim that inverts the FDA ladder.
Start with what is good, because it is real and it is unusual. This company ran a prospective, randomised, double-blind, sham-controlled trial with a visually identical placebo patch, registered it on ClinicalTrials.gov as NCT06505005, enrolled 118 people and published it in Pain and Therapy, a peer-reviewed Springer title indexed in PubMed. Most companies in this category never come close. There is no FDA warning letter, no FTC action, no attorney-general action, no class action and no court finding anywhere. The self-regulatory inquiry that did open concerned income claims by the salesforce and closed administratively after the company removed nine of ten posts, retrained compliance and paid for third-party social monitoring - remediation the self-regulator called necessary and appropriate, with no referral onward. The plan is a unilevel rather than a binary. Entry is $50. The product cannot hurt anyone. Take all of that seriously before reading the rest.
The regulatory framing is the most useful thing here and it takes one paragraph. Three separate things get collapsed in this marketing. FDA establishment registration and device listing is a clerical filing - a firm tells the agency it exists and what it makes; the agency reviews nothing and endorses nothing, and prohibits anyone from representing registration as approval. A 510(k) clearance is a substantive submission with evidence reviewed; none exists here. Premarket approval is the top of the ladder and is not in play at this risk class. Separately, the FDA’s general-wellness policy is an enforcement-discretion carve-out for low-risk products whose intended use stays inside general wellness. Presenting "FDA registered" as "the highest level of regulatory approval," which TINA.org documented in July 2024, takes the lowest and most clerical of those and calls it the highest. And the company’s own trademark filing describes the product to the USPTO as Class 10 medical apparatus for pain management and acupressure, while the Ignite page carries a dietary-supplement disclaimer that has no application to devices at all.
The economics are where the grade comes from and they are short. There is no income disclosure statement in the United States, Canada, the United Kingdom or Germany - no median, no average, no share earning nothing. In its place the official Associate Handbook publishes "You Plus 3 · Them Plus 3," a 60-day plan paying $390 at Qualified Associate and $1,651 at Team Leader, in which every component is triggered by somebody else enrolling onto a kit and a $90 autoship, and in which retail commission is explicitly described as "extra." Qualifying by selling costs $120 of volume where qualifying by buying costs $90. The year-one cost floor is $1,130 basic or $1,629 for full bonus access, before events, tools and travel that are priced nowhere. And the one public record of how the company responds to complaints is a BBB file in which every complaint over three years is logged unanswered. One good trial does not carry that. The trial is about the product; the grade is about the deal.
Buy the patch as a customer if you want it, and skip the plan entirely
The Preferred Customer subscription is the same $60 pack the associate discount is built on, without a $50 enrollment, a $250–$650 Launch Kit, a $90 monthly qualification floor or a rank ladder. If the RESTORE result persuades you, buy the one patch that trial covered, and know before you order that returns are accepted only in unopened original packaging with the buyer paying return postage.
Ask your sponsor for the income disclosure, and note what happens next
There isn’t one, in any market. That single request separates a sponsor who knows the file from one who does not. If they answer with the handbook’s $390 or $1,651, ask what proportion of associates reach it and where that proportion is published. The absence of an answer is the answer, and it is the same absence a self-regulator flagged in 2025 when it applied the standard that earnings representations must reflect what the average participant is likely to achieve.
Get the Policies and Procedures and the Associate Agreement in writing before you sign
Both return 404 and 403 at their public URLs. Ask for PDFs by email and read the termination, customer-ownership, non-solicitation and buyback clauses before any money moves. If a company will not show you the contract that governs your business until after you have joined, you have learned something more useful than anything in the clauses.
If the interest is the science, sell the comparison instead of the patch
Vibrotactile stimulation and neuromatrix pain modulation are legitimate research fields with genuine search demand, and the interesting content is exactly the content this field is not free to write: what a registered sham-controlled trial does and does not establish, what FDA registration means against clearance, and how to read a sponsor-funded study. That is a merchant business with no kit, no monthly volume floor and no permission needed to publish.
Nine dimensions, weighted
Dimension profile
Further from center is better. Hover any point.
Hard caps that bind here
The lowest binding cap wins, regardless of the weighted arithmetic.
What we read
Every source below links to the document itself. Tier 1 is a primary record - the company’s own plan, policy or disclosure, a court filing, a regulator’s decision or an SEC filing. Tier 2 is a self-regulatory or secondary regulator record, tier 3 reporting or academic work, tier 4 an open-market price comparison. Where a document can be moved or withdrawn, an archived copy is linked beside it. If a link is dead when you try it, that is a correction we want.
- The Super Patch Company Associate Handbook, Version 4.0 (JavaScript flipbook, publication ID 814876) - p.46, the "You Plus 3 · Them Plus 3" 60-day earnings illustration
The Super Patch Company Associate Handbook v4.0 (JavaScript flipbook, publication ID 814876) - p.13 direction to the Policies and Procedures and Associate Agreement, p.23 template-modification rules, p.24 Practitioners Program free enrollment at 50% off retail, p.30 $50 Welcome Kit with $75 of product and "25%++" wholesale, pp.40–41 rank ladder, TGQV thresholds, $90/$120 qualification gate, $200 Hat Trick and $400 All-Star bonuses and the two irreconcilable renderings of the unilevel percentages, p.46 the "You Plus 3 · Them Plus 3" 60-day illustration paying $390 and $1,651
- Super Patch Independent Associate Compensation Plan, September 2024 detailed edition (PDF) - $50 Associate Welcome Kit, $200 Hat Trick Bonus and $400 All-Star Bonus qualification rules
- BehindMLM, "The Super Patch Company Review: Vibrotactile technology?" - the eight-rank ladder and TGQV thresholds, the six-level unilevel percentages, generational bonus, rank achievement bonuses and the $275/$420/$650 launch-kit ladder
- TINA.org, "What You Should Know about Super Patch," 1 July 2024 - "FDA registered" presented as "the highest level of regulatory approval," only four of twelve patches registered as Class I devices, associate use of the FDA logo, and the disease claims cataloged across associate channels, the company site and its own YouTube training channel
TINA.org, "What You Should Know About Super Patch," July 2024 - no income disclosure in any market; "FDA registered" presented as "the highest level of regulatory approval"; four of twelve patches listed as Class I devices; associate use of the FDA logo without authorization; disease claims including wheelchair users walking, addiction, Parkinson’s, MS, COVID, arthritis, ADHD and diabetic neuropathy on associate channels, the company site and its own YouTube training channel; refund terms restricted to unopened packaging with buyer-paid return shipping; $50–$999 enrollment range
- Fason J, Hurwitz P, Gudin J, "Reducing Pain and Improving Mobility Using Haptic Patch Technology: Results of the RESTORE Study," Pain and Therapy vol 14 no 6, 1797–1807, December 2025 (DOI 10.1007/s40122-025-00780-0)
Fason J, Hurwitz P, Gudin J, "Reducing Pain and Improving Mobility Using Haptic Patch Technology: Results of the RESTORE Study," Pain and Therapy vol 14 no 6, December 2025, PMID 41057672 - prospective, randomised, double-blind, vehicle-sham-controlled, n=118 (64 active, 54 control), BPI severity and interference plus Schober, goniometer and inclinometer range of motion at days 7 and 14; registered as ClinicalTrials.gov NCT06505005, sponsor "SuperPatch Limited LLC," start 20 September 2024
- PubMed record for the RESTORE Study, PMID 41057672 - including the conflict-of-interest declaration that all three authors were compensated by, or lead, Clarity Science LLC
- ClinicalTrials.gov registration NCT06505005, "RESTORE (Relieving Pain and Improving Sleep…)" - sponsor SuperPatch Limited LLC, collaborator Clarity Science LLC, start date 20 September 2024
- Gudin J, Fason J, Hurwitz P, "Using Haptic Technology for Pain Reduction and Functional Improvement," Anesthesia & Pain Research 2024;8(1):1-8 (PDF) - n=168 split 148 treatment to 20 control; funding stated as Srysty Holding Co.; all authors compensated by Clarity Science LLC
Gudin J, Fason J, Hurwitz P, "Using Haptic Technology for Pain Reduction and Functional Improvement," Anesthesia & Pain Research, 2024 - prospective IRB-approved observational and self-described non-randomised, n=168 split 148 treatment to 20 control, 47% versus 6% BPI severity decrease, 75% versus 0% satisfaction; funding stated verbatim as "funded by Srysty Holding Co., the distributors of the FREEDOM Super Patch with VTT"; all three authors compensated by Clarity Science LLC or affiliates
- Hurwitz P et al., "Haptic Vibrotactile Trigger Technology: Disrupting the Neuromatrix to Reduce Pain Severity and Interference: Results from the HARMONI Study" (PDF hosted by Super Patch) - the earlier 148-subject observational study the 2024 paper builds on
- DSSRC Case #242-2025: Administrative Closure - The Super Patch Co., closed December 2025 (ten challenged income claims, nine posts removed, tenth poster found unaffiliated, third-party social-monitoring vendor engaged)
BBB National Programs, Direct Selling Self-Regulatory Council Case #242-2025, closed 9 December 2025 - inquiry into salesforce income claims including "financial freedom" and "unlimited earning potential"; nine of ten posts removed, tenth poster found unaffiliated, compliance retraining and third-party social-monitoring vendor engaged; corrective action found "necessary and appropriate"; FTC Business Guidance for Multi-Level Marketing applied, requiring representations to "reflect what the average participant is likely to achieve"; administratively closed with no FTC referral
- DSSRC Case #242-2025 decision, full text with the verbatim challenged claims (PDF copy published by TINA.org)
- "List of October 2021 Recipients of the FTC's Notices of Penalty Offenses Concerning Money-Making Opportunities and Concerning Deceptive or Unfair Conduct around Endorsements and Testimonials," updated 25 October 2021 (PDF) - the published recipient list
Federal Trade Commission, Notices of Penalty Offenses Concerning Money-Making Opportunities, October 2021 - published recipient list, retrieved and confirmed to contain "VoxxLife" and to contain no entry for Super Patch, Voxx or Srysty; sent to over 1,100 companies as a notice rather than a charge, with civil-penalty exposure reported at up to $51,744 per violation at the time
- FTC, Notice of Penalty Offenses Concerning Money-Making Opportunities (PDF) - the substantive determinations the Notice puts recipients on notice of
- FTC press release, "FTC Puts Businesses on Notice that False Money-Making Claims Could Lead to Big Penalties," 26 October 2021 - over 1,100 recipients, civil-penalty exposure of up to $43,792 per violation at the time, and the statement that presence on the list does not suggest wrongdoing
- Better Business Bureau business profile, The Super Patch Company Ltd, 1 – 350 Britannia Rd E, Mississauga, Ontario - not accredited, rating reasons stated as "Failure to respond to 9 complaint(s)" and "9 complaint(s) filed against business"
Better Business Bureau profile and complaint file, The Super Patch Company Ltd, Mississauga, Ontario - F rating, nine to ten complaints over three years all logged as unanswered; December 2024 complaint recording an $818.12 order refunded at $586.15 after a $231.97 restocking fee against an advertised 100% money-back guarantee; July 2024, March 2025 and May 2025 complaints recording unanswered cancellation requests and months-long refund delays
- Better Business Bureau complaint file, The Super Patch Company Ltd - nine total complaints in three years, two closed in the last twelve months, with individual complaint texts and statuses
- USPTO trademark application serial no. 97356960, THE SUPER PATCH COMPANY, applicant Srysty Holdings Inc., filed 11 April 2022, International Class 10 - TSDR status view
USPTO application 97356960, The Super Patch Company, applicant Srysty Holdings Inc., filed 11 April 2022, published for opposition 17 October 2023 - International Class 10 medical apparatus, "self-adhesive patches bearing fine ridge patterns for stimulating trigger points for energy, pain management, mobility, stability and balance" and "apparatuses for acupressure therapy"; no 510(k) clearance located in the FDA premarket notification database for Super Patch, Srysty or VoxxLife
Not established by this document: No 510(k) premarket notification record exists for Super Patch, Srysty Holdings or VoxxLife; the FDA 510(k) database returns no result, and an empty database query has no citable permalink, so the negative is evidenced here through the Class I "TAPE, ORTHOPEDIC" (product code HXT) listing in MAUDE instead.
- FDA MAUDE adverse event report, THE SUPER PATCH COMPANY LTD LLC - product code HXT, "TAPE, ORTHOPEDIC," evidencing the Class I device classification under which the patches are listed rather than 510(k)-cleared
- Quebec Pain Research Network, "Have you heard about the new vibro-tactile technology for pain management?" - physical examination finding "a simple piece of flexible, transparent plastic, decorated with a raised pattern," "no vibrations are detectable and… no apparent internal components," peer-review and randomisation deficiencies, undisclosed patch composition, and Health Canada non-approval; also the $60 per 28-pack price
Quebec Pain Research Network assessment of vibrotactile patch technology - physical examination finding "a simple piece of flexible, transparent plastic, decorated with a raised pattern" with "no vibrations are detectable and there are no apparent internal components," peer-review and randomisation deficiencies in the supporting literature, undisclosed patch composition, and confirmation that the product is not approved by Health Canada
- Quebec Pain Research Network, "Super patch, what is it?" 18 April 2024 - the Radio-Canada La facture segment, the predatory-journal finding, and Health Canada's advice against use
- Direct Selling News, "The Super Patch Company: Driven by Data, Destined to Grow," 20 February 2025 - company-supplied $60M for 2023 with expectations to double for 2024, "people making over $100,000 a month," "the first three millionaires in the company," and the named executive list
BusinessForHome company page and November 2024 article (revenue series $10M 2022, $55M 2023, $100M 2024, $100M and 0% growth 2025 - all unaudited trade estimates); Direct Selling News, 20 February 2025 (company-supplied $60M for 2023, ~$120M projection, "$100,000 monthly" earners, "three millionaires," executive list); The Express syndicated to AOL, June 2026 ("$200M revenue run rate"); DSN Global 100 for 2026, on which the company does not appear; Trustpilot company page, 1,074 reviews at TrustScore 4.0; retail pricing at $60 per 28-pack and SmartShip at $60/month
Not established by this document: The June 2026 Express article syndicated to AOL carrying the "$200M revenue run rate" figure could not be located at a retrievable URL. The DSN Global 100 for 2026 is cited on other companies in this corpus; Super Patch's absence from that list is a negative that has no separate citable document beyond the published list itself.
- Business For Home, "The Super Patch Company Ranked As Triple AAA+ Opportunity For 2024 And 2025," November 2024 - $55M 2023 revenue estimate, 450% growth from 2022, 47% compensation-plan payout estimate, $90–$100M 2024 projection
- Direct Selling News, "Momentum," 1 December 2024 - Jay Dhaliwal interview giving "$60M 2023 revenue" as key stat and explaining the $60 price point derived from a 10,000-person pricing exercise
- Trustpilot company page, superpatch.com - 1,074 reviews, with the refund-delay and return-restriction complaints quoted in the report
- The Super Patch Company official storefront - retail pricing and SmartShip terms
What we could not get
- Any audited financial statement, and any corporate registry filing for The Super Patch Company Ltd, Srysty Holdings Inc. or The Super Patch Company GmbH - incorporation dates, directors of record, share structure and filing history could not be retrieved in Canada or Germany, no auditor is named anywhere, and every revenue figure in this report is company-supplied or trade-estimated. The "$100M flat in 2025" and "$200M run rate in 2026" figures cannot be reconciled with one another.
- The full text of the Policies and Procedures and the Associate Agreement, both of which return 404 and 403 at their public URLs. Termination rights, customer ownership, non-solicitation, health-claim rules, income-claim rules and buyback terms are reconstructed from the handbook, the DSSRC decision and observable behavior - not read.
- The current kit ladder. Sources give $250/$450/$650, $275–$650, $50–$999, "$549 to access all bonuses" and "over $600," apparently because kits were repriced between handbook versions and across markets. The exact National Leadership Pool percentage is likewise 1% in one source and 3% in another, and the handbook page retrievable states only that a pool exists.
- The reconciled unilevel level percentages, which the official handbook renders differently on pages 40 and 41 - meaning a prospect cannot compute an expected commission from company material, and neither can this report.
- Independent confirmation of FDA establishment registration for the four named patches. A watchdog reports four of twelve registered as Class I; direct queries against the openFDA registration-and-listing API on proprietary-name and registrant-name fields, and against the acupressure-device product code, returned no matching records. The null result may reflect API field matching rather than absence, so the watchdog finding is adopted while noting it could not be reproduced.
- Any substantiation for the Ignite "25 Percent Improvement in Resting Metabolic Rate" claim, for the "RECOMMENDED BY 1,000’S OF DOCTORS" banner, or for the claimed "16 published studies." No RMR study, no doctor count or methodology, and no enumerated study list could be located; PubMed indexes two papers.
- The customer-to-associate sales ratio - the decisive number for whether commissions are funded by outside demand or by participant purchasing. It is not published and cannot be derived, and neither can event, convention or tools costs for participants.
- VoxxLife’s current operating status and whether its distributor base was formally migrated onto this offer; whether any UK or EU regulator has an unpublicised file open; whether the trade-site coverage carrying the revenue estimates was paid for, the site operating a "Get Published" route with no sponsorship disclosure on these articles.
Not advice
This is independent analysis for decision-making, not legal, financial or investment advice. Allegations reported by third parties should be verified against primary court and regulatory records before any decision.
Researched by Claude. Reviewed by an editor.
Every report is researched and written by Claude, Anthropic’s AI assistant, from the company’s own plan documents, policies, terms and regulatory file - then reviewed before publication by Rob Fore, who checks the sources and the stage-label on every allegation.
- Nine weighted dimensions, published with their weights
- The editor checks the evidence and cannot change the number - the build rejects any page whose grade does not reconcile to its own arithmetic
- Every affiliate position we hold is disclosed on the report it touches
- No company has paid for a grade, and no report carries an affiliate link
Looking at something else?
Enter any company name or website. If a report exists it opens instantly; if not, we start one.
Super Patch - frequently asked
QIs Super Patch FDA approved?
QDoes the Super Patch research hold up?
QHow much do Super Patch associates earn?
QHow much does it cost to join Super Patch?
QHas any regulator taken action against Super Patch?
Author, editor and publisher
This report was researched and written by Claude, Anthropic’s AI assistant, working from primary documents - Super Patch’s own compensation plan, its policies and procedures, its terms of service, its income disclosure statement where one exists, and its regulatory and self-regulatory file. It was scored against nine weighted dimensions that are published in full, with their weights, on the methodology page.
Before publication it was reviewed by Rob Fore, who checks every source link, every figure against the document it came from, and every allegation against its stage-label - an investigation is not a finding, a warning letter is not an enforcement action, and a filed claim is not a verdict.
The editor does not set the grade. The published score is the weighted composite of the nine dimension scores, and the build refuses to emit a page where the two disagree by more than 0.06. A grade moves when the evidence moves it and not otherwise.
Rob Fore has marketed online since 1996, wrote Online MLM Marketing (2014), and is CEO of Listech Inc, the Nevada corporation that publishes this site. He holds affiliate positions in companies graded here - including LiveGood, which this site grades D, SendOutCards, which it grades C−, and the Home Business Academy, which it grades B−. Those positions are disclosed on the reports they touch, and changed nothing on this page.
About the author and our conflicts · Contact the editor · Corrections: corrections@opportunitygrade.com
Tell me if this grade changes
Super Patch is graded D- as of July 29, 2026. Grades move when the evidence moves - a new income disclosure, a regulatory action, a rewritten compensation plan. Leave your address and you will get one email if this one does.
One email when the grade moves, and nothing else. We will never use your address to promote an income opportunity of any kind, we do not sell, rent or share the list, and it is stored on our own infrastructure rather than with any company graded here. Unsubscribe removes everything.
Corrections
Every factual claim on this page is sourced, and the ones we could not stand up are named in the unable to verify list above. If something here is wrong, we want to know, and we would rather hear it from Super Patch than from a reader.
Write to corrections@opportunitygrade.com. Point at the specific sentence and send the document that contradicts it - a plan document, a filing, an income disclosure, a policy page. We will check it against the primary source, correct the page if it is wrong, and say in the report that it was corrected and when. A grade moves if the evidence moves it.
This address reaches a person, not a form. We do not require a takedown demand, an NDA or a lawyer to accept a correction, and we do not remove a report because a company disputes its conclusion - only because the underlying facts turn out to be wrong.